ArticleScientific reports2025
Correlation between virological response and portal vein thrombosis in patients with chronic hepatitis B.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Preoperative portal vein thrombosis did not compromise long-term survival after liver transplantation with proper portal inflow reconstruction.Translational gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein thrombosis (PVT) is an important complication of liver cirrhosis, especially in patients with chronic hepatitis B (CHB). Previous studies have revealed that hepatitis B virus (HBV) infection and several serological indicators are associated with PVT; however, no predictive model including virological indicators of PVT in cirrhosis patients with CHB has been established. A retrospective cohort study including 252 CHB patients at the Affiliated Hospital of Qingdao University between January 1, 2012, and December 31, 2023, was performed. Baseline data were collected. PVT outcomes and antiviral virological responses were subsequently evaluated. We recognized risk factors and their hazard ratios. Propensity score matching (PSM) analysis was used to control for confounding factors. A clinical predictive model of PVT in CHB patients was established and verified. During a median follow-up time of 2568 days, 28 patients (11.11%) developed PVT. There were significant differences in age, portal vein diameter, spleen major axis, antiviral therapy time, prothrombin time (PT), blood platelet count, aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), alpha-feto protein (AFP), D-dimer, international normalized ratio (INR), low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (TC), serum hepatitis B virus deoxyribonucleic acid (HBV DNA) loads and levels after antiviral therapy, complications associated with hepatocellular cell cancer cirrhosis level, and antiviral responses between PVT patients and non-PVT patients. The effect of antiviral therapy was worse in more severe cirrhosis. There were greater PVT risks in patients with VBT antiviral responses, larger major axes in the spleen, and higher hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (HBsAb) levels. After controlling for confounding factors with PSM analysis, there was still a higher PVT risk in patients with adverse virological responses. A predictive nomogram for PVT in CHB patients was established and validated. PVT is a common complication in cirrhosis patients with CHB. Favorable virological responses are beneficial for lowering the risk of PVT in CHB patients. HCC, virological response, age, portal vein diameter, splenic major axis, PT, PLT, HBsAg, and HBsAb can be used to predict PVT in CHB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.